Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
60 Degrees Pharmaceuticals Inc. (SXTPW) is a clinical-stage company developing innovative therapies for infectious diseases, notably malaria prophylaxis through its FDA-approved product ARAKODA. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and healthcare professionals will find timely updates on clinical trials, partnership agreements, and therapeutic advancements. Our curated collection includes press releases covering drug development progress, peer-reviewed research findings, and strategic initiatives in tropical medicine.
Key content areas include malaria prevention updates, babesiosis treatment research, FDA regulatory communications, and collaborative studies with academic institutions. All materials are sourced directly from company filings and verified channels to ensure reliability.
Bookmark this page for streamlined access to SXTPW's latest developments in infectious disease therapeutics. Check regularly for updates on pipeline innovations and clinical trial data impacting global health outcomes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has entered into a research agreement with Tulane University to study tafenoquine's effectiveness against Borrelia (Lyme disease) and Bartonella bacteria in cell culture. These pathogens, along with Babesia, are known as the "3Bs" commonly found in tick-borne illnesses.
The study aims to evaluate tafenoquine, an FDA-approved antimalarial drug marketed as ARAKODA®, for potential treatment of co-infections in babesiosis patients. Currently, tafenoquine is undergoing babesiosis trials at several sites. The drug's safety for malaria prophylaxis has been validated through six randomized, controlled trials lasting up to 12 months, though it remains unapproved for treating babesiosis, Borrelia, or Bartonella infections.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has closed its previously announced public offering, raising $5 million in immediate gross proceeds. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) with accompanying Series A-1 and A-2 warrants at $1.90 per share.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. If the Series A-2 warrants are fully exercised, the company could receive up to an additional $5 million in gross proceeds. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has announced the pricing of a $5 million public offering with potential additional proceeds of up to $5 million through warrant exercises. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) at $1.90 per share, along with Series A-1 and A-2 warrants.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent, with closing expected around July 16, 2025. The company plans to use proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced the potential market size for ARAKODA® (tafenoquine) in treating human babesiosis, projecting maximum annual sales of $245 million and a cumulative market value of $1.1 billion through patent expiration in 2035.
The market assessment is based on comprehensive research including a 6,000-patient nationwide survey and feedback from 300 healthcare professionals. The company estimates a total addressable market of 380,000 patients annually.
Currently, three clinical trials are underway or planned to evaluate tafenoquine's safety and efficacy. The company expects to submit a New Drug Application (NDA) to the FDA in 2026, pending positive trial results.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.
The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.
However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $535.4 thousand attributed to increased sales, investor-related services, and stock-based compensation. The company reported a net loss of $2.01 million ($1.56 per share) in Q1 2025, compared to a net income of $308.7 thousand ($1.83 per share) in Q1 2024, largely due to a $1.74 million change in fair value of derivative liabilities.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reveals groundbreaking survey results suggesting babesiosis disease burden in the US is significantly higher than CDC estimates. The survey, conducted among 6,000 US adults, found that 1.26% of respondents (equivalent to ~3 million people) reported receiving a babesiosis diagnosis in their lifetime, compared to CDC's 1,834 reported cases in 2020.
The study indicates that approximately 17% of babesiosis patients experienced illness lasting six months or more, suggesting around 570,000 US adults have faced chronic disease. Additionally, 3.7% of respondents (~9.9 million Americans) reported experiencing chronic fatigue lasting longer than six months, with 56% of these individuals having received a formal Chronic Fatigue Syndrome diagnosis.
This significant disparity between survey findings and CDC statistics suggests babesiosis may be substantially underdiagnosed or underreported, potentially indicating a larger market for effective treatments.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.
The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.
FAQ
What is the current stock price of 60 Degrees Pharm (SXTPW)?
